Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE:CLVT) has released a new report titled Extending the Human Lifespan, exploring advancements in anti-aging science and the development of potential drugs. The report highlights a significant rise in the global population aged 65 and older, creating a demand for solutions to enhance both lifespan and quality of life. Key findings include 139 ongoing trials for seven existing drugs that might extend lifespan, raising $1.95 billion for aging-related companies since 2020. However, there are concerns regarding gender disparities in aging research.
Clarivate Plc (NYSE:CLVT) announced the retirement of Jerre Stead as CEO, effective September 1, 2022, after three years of leadership during which the company nearly tripled in size. Jonathan Gear has been appointed as CEO-elect, starting July 11, 2022, with a strong background in technology and data services, previously serving as CFO of IHS Markit. Mr. Stead will transition to Non-Executive Chair of the Board, emphasizing the confidence in Mr. Gear to lead the company forward. Clarivate aims to position itself as a leading provider of innovative solutions.
Clarivate Plc (NYSE: CLVT) announced it will release its second quarter 2022 financial results on August 9, 2022, prior to market opening. The earnings report and financial details will be available on the investor website. A conference call and webcast to discuss the results will occur on the same day at 9:00 AM Eastern Time. Interested parties can join the call via a dedicated phone line or access the live webcast through the company’s investor relations site. A replay will be available for a limited time following the call.
Clarivate Plc (NYSE: CLVT) has been selected for the second consecutive time to provide citation data for the Australian Research Council's Excellence in Research for Australia (ERA) 2023. This initiative aims to evaluate research excellence across Australian universities. Utilizing The Web of Science™, Clarivate will support the ARC in assessing research quality through citation indicators and peer reviews. Clarivate has been involved with ERA since its inception in 2010, continually implementing improvements to enhance research evaluations.
Summary not available.
Clarivate Plc (NYSE: CLVT) has released its 2022 Journal Citation Reports (JCR), highlighting ongoing increases in citation impact for journals publishing COVID-19 research. Notably, The Lancet now holds the top Journal Impact Factor of 202.731, surpassing the New England Journal of Medicine, while Nature becomes the first journal to exceed one million citations in a year. The JCR assesses over 21,000 journals with rigorous criteria, emphasizing the profound influence of COVID-19 on academic publishing.
Clarivate Plc (NYSE: CLVT) announced that Jerre Stead and Jonathan Collins will present at investor conferences in June 2022. Key dates include the Stifel 2022 Cross Sector Insight Conference on June 7, 2022, at 9:10 AM ET, and the William Blair’s 42nd Annual Growth Stock Conference on June 9, 2022, at 2:20 PM ET. Live webcasts will be available for both events, with replays accessible afterwards. Clarivate aims to provide solutions that accelerate innovation across various sectors, including Life Sciences and Technology.
Summary not available.
Clarivate Plc (NYSE:CLVT; CLVT PR A) announced a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. This dividend will be paid in cash on June 1, 2022, to shareholders of record as of May 13, 2022. This decision reflects the company's commitment to returning value to its shareholders while maintaining its focus on providing trusted information and insights that accelerate innovation.
Clarivate Plc (CLVT) reported strong financial results for Q1 2022, with revenues soaring to $662.2 million, a 54.6% increase year-over-year. Organic revenues rose 4.4%, while net income improved by $106.8 million to $50.8 million. Adjusted EBITDA also saw significant growth, up 59.2% to $262.3 million. Subscription revenues increased 69%, driven by the ProQuest acquisition. However, net cash provided by operating activities decreased by 61.3% to $67.4 million, primarily due to payroll payments. The company reaffirmed its positive outlook for 2022.